Beactica Therapeutics

Beactica's Head of Chemistry, Peter Brandt, to present the YAP-TEAD targeted degrader programme at the Discovery Europe 2024 conference in Basel, Switzerland, on May 23.#oncology #HippoPathway #drugdevelopment #targetedproteindegradation #tpd

Peter Brandt presenting late-breaking research poster “Degraders of TEAD based on interface 3 binders” at the AACR Annual Meeting in San Diego. Results were well received and further evidence we're on the right track! Many thanks to our collaborators at @ncats_nih_gov. #AACR24

We are delighted to welcome Jarl Ulf Jungnelius M.D. to the Board of Directors. #oncology #therapeutics #leadership Full story here: beactica.com/press/beactica-…

Beactica's Head of Chemistry, Peter Brandt, to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023 in Boston on May 25. Full story: beactica.com/press/beactica-… #oncology #HippoPathway #drugdevelopment #targetedproteindegradation

Beactica Therapeutics' Head of Discovery, Dr Konrad Koehler, to present LSD1 programme update at the @AACR Annual Meeting in Orlando, Florida. #AACR23 #LSD1 #orphandrug #GBM. Read full story: beactica.se/press/beactica-t…

BEA-17 has been granted Orphan Drug Designation for the treatment of glioblastoma by the U.S. Food and Drug Administration (FDA). Read full story here: beactica.com/press/beactica-….

This week marked the first face-to-face meeting of our collaboration with @dundeeuni to develop WRN degraders to target genetically defined cancers. What a difference it makes to meet in person! Many thanks to the team at @UoDLifeSciences, @DDU_Dundee and @mrcppu for a great day.

Beactica Therapeutics' CEO @PerKallblad will be at #BioEquity Europe in Milan next week to talk to investors about leveraging synthetic lethality to tackle genetically defined cancers. #cancer #precision #therapeutics

Beactica's Head of Chemistry Peter Brandt is at the AACR Annual Meeting in New Orleans to scan the horizon on synthetic lethality and genetically defined cancers. #cancer #AACR22 #WRN

We are delighted to welcome Peter Brandt as Head of Chemistry and Christina Herder and @TedFjallman to the Board. Their extensive experiences will be very valuable as we now gear up towards new goals in our fight against cancer. Full story: beactica.se/press/beactica-t…

The first face-to-face Board meeting for 18 months. An exciting day focussed on strategies for making the most of recent advances in our pipeline of first-in-class cancer therapeutics. A special welcome to new board members Christina Herder and @TedFjallman from Flerie Invest.

Synthetic lethality’s second wind - An overview of this fast-moving field with a mention of Beactica's WRN helicase collaboration with @dundeeuni and @DDU_Dundee biocentury.com/article/63574…

We are very pleased to announce this partnership with Oscotec, a company committed to building a strong clinical pipeline of targeted therapeutics in immunology and oncology. Full story at beactica.com/press/beactica-…. #breakthrough #cancer #therapeutics

4 years of hard work today culminated in @E_FitzG's successful defence of his Ph.D. at @UU_University. Many congrats Dr Ted! A special mention to @HelenaDanielson for top supervision during this industrial Ph.D. studentship! #newdrughunter #FBDD #biosensors #fragnet

Congratulations to @E_FitzG on his latest publication. The work was performed whilst doing his Ph.D. at Beactica and in collaboration with excellent scientists in Uppsala, South San Francisco and Amsterdam. #FBDD #biodesy #SciLifeLab pubs.rsc.org/en/content/arti…

We are excited too embark on this collaboration with @dundeeuni, @DDU_Dundee and @mrcppu, institutions with impressive depths of expertise in the biological sciences beactica.se/press/beactica-t… #cancer #therapeutics #DNArepair #PROTACs